Business

April 29, 2014 10:10 AM

Pozen shares fall after FDA finds problems with new drug application

Pozen shares fell more than 10 percent Monday after the Chapel Hill company announced that federal regulators have informed the company that its new drug application cannot be approved in its current form.

Related content

Comments

Videos

More Videos

Transgender CEO speaks out on NC's HB2 02:49

Transgender CEO speaks out on NC's HB2

Two-year-old girl from Brazil sees her mother for the first time thanks to surgery 02:34

Two-year-old girl from Brazil sees her mother for the first time thanks to surgery

Inside Counter Culture Coffee's new headquarters 01:41

Inside Counter Culture Coffee's new headquarters

HB2 fallout impacts High Point Furniture Market 00:56

HB2 fallout impacts High Point Furniture Market

Sights & sounds of a Cuban tobacco harvest 01:04

Sights & sounds of a Cuban tobacco harvest

White House says Zika is worse than previously thought 02:09

White House says Zika is worse than previously thought

Blue Cross CEO and chief operating officer address employees at March meeting 01:37

Blue Cross CEO and chief operating officer address employees at March meeting

Apple announces product updates and new headquarters 01:23

Apple announces product updates and new headquarters

Phononic solid-state cooling tech in RTP 01:10

Phononic solid-state cooling tech in RTP

Implus a growing Durham NC business 01:24

Implus a growing Durham NC business

CEO Brad Wilson of Blue Cross Blue Shield 01:55

CEO Brad Wilson of Blue Cross Blue Shield

Share Video

Today's Market

Nasdaq
Powered by Barchart

Editor's Choice Videos